Michaela F. Kerekes

Learn More
OBJECTIVES To assess the benefits and harms of reboxetine versus placebo or selective serotonin reuptake inhibitors (SSRIs) in the acute treatment of depression, and to measure the impact of potential publication bias in trials of reboxetine. DESIGN Systematic review and meta-analysis including unpublished data. DATA SOURCES Bibliographic databases(More)
BACKGROUND Clinical trial results registries may contain relevant unpublished information. Our main aim was to investigate the potential impact of the inclusion of reports from industry results registries on systematic reviews (SRs). METHODS We identified a sample of 150 eligible SRs in PubMed via backward selection. Eligible SRs investigated randomized(More)
BACKGROUND Access to unpublished clinical study reports (CSRs) is currently being discussed as a means to allow unbiased evaluation of clinical research. The Institute for Quality and Efficiency in Health Care (IQWiG) routinely requests CSRs from manufacturers for its drug assessments. Our objective was to determine the information gain from CSRs compared(More)
OBJECTIVE To investigate to what extent three types of documents for reporting clinical trials provide sufficient information for trial evaluation. DESIGN Retrospective analysis DATA SOURCES Primary studies and corresponding documents (registry reports, clinical study reports, journal publications) from 16 health technology assessments of drugs(More)
OBJECTIVE To determine the short-term antidepressant efficacy and tolerability of duloxetine and venlafaxine vs. each other, placebo, selective serotonin reuptake inhibitors (SSRIs), and tri- and tetracyclic antidepressants (TCAs) in adults with major depression. METHOD Meta-analysis of randomised controlled trials identified through bibliographical(More)
Systematic reviewers are increasingly trying to obtain regulatory clinical study reports (CSRs) to correct for publication bias. For instance, our organization, the Institute for Quality and Efficiency in Health Care, routinely asks drug manufacturers to provide full CSRs of studies considered in health technology assessments. However, since cooperation is(More)
  • 1